Europe’s biggest cancer congress ESMO wraps up today, having delivering its fair share of major studies and talking points in cancer treatment over five days.
While much of the research at ESMO is based on breaking new ground and upping the ante against cancer, some studies focus on fine-tuning existing treatment to improve patient quality of lif
New phase 3 data presented at ESMO earlier today suggests Tagrisso could be a major step forward in treating patients with EGFR positive non-small cell lung cancer.
Clovis has confirmed a major victory with its ovarian cancer treatment Rubraca, the drug showing significant benefits for all patients in a maintenance setting – and better results than its
Seismic Therapeutic has raised $121 million in second-round financing that will be used to take its two lead drugs through early-stage clinical testing.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio